Cumberland Pharmaceuticals Posts $2.16 Million Q3 Revenue, $0.07 Loss Per Share From Continuing Operations

Cumberland Pharmaceuticals Inc. posted $2.16 million in revenue for the quarter ended Sept. 30, 2026, and $77.8 million in GAAP net income, including an $81.1 million gain on disposal of discontinued operations.

The company recorded a $1,122,071 loss from continuing operations, or $0.07 per share on both basic and diluted bases. Net income totaled $77,777,752, and diluted GAAP earnings per share were $5.07.

Transition-services revenue was $1.95 million, while net revenue totaled $206,356. The quarter was Cumberland’s first after the July 1, 2026, closing of its transaction with Apotex Health. Cumberland’s commercial brands and organization were integrated into Apotex’s U.S. branded business.